Align Technology Inc (ALGN)
Health Care · Health Care Supplies · US stock · S&P 500 component
$147.31
▼ -2.03 (1.36%)
Fair valueFair
$187 +26.6% to fair value
$93fair band $131–$242$280
Day's range
$146.14 – $152.27
52-week range
$128.65 – $200.44
About Align Technology Inc
Align Technology makes the Invisalign system of clear aligners used to straighten teeth, along with digital scanners and software that dentists and orthodontists use to plan treatment. The company sells aligners and scanners to dental practices, which in turn treat patients. Revenue is earned from the number of aligner cases shipped and from sales of scanning equipment and related services. Its results depend on consumer spending on elective dental care.
Revenue for the last twelve months was $4.1 billion, and it grew by 2.6% a year over three years. The operating margin is 13.2%, and return on invested capital reached 13%. It does not pay a dividend. Its X-Ray Score is 60 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $128.65 – $200.44Volume 953,000Daily, split-adjusted
Vitals
Market cap$10.5B
52-week range$128.65 – $200.44
Volume (last day)953,000
P/E (TTM)25.7
EBIT / EV yield5.8%
Free-cash-flow yield6.0%
Dividend yieldNo dividend
Revenue (TTM)$4.1B
Net income (TTM)$413M
Operating margin13.2%
Return on capital12.7%
Debt incl. leasesData missing
Cash & securities$1.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$187model spread $180 – $195
Fair
+26.6% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $147
Undervalued < $131Fair $131 – $242Overvalued > $242
10-year DCF (market-scaled)
$185
Peer multiples
$194
Earnings power floor (not blended)
$100
Fundamentals-adjusted multiple
$181
Growth the price implies
12.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
75/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield5.8%
Free-cash-flow yield6.0%
Fair value vs price1.3×
Growth
Weak
41/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)2.6%
EPS growth (3y)7.0%
Growth consistency80%
Profitability
Fair
57/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital12.7%
Operating margin13.2%
Gross profitability43.9%
Financial health
Fair
68/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score7 / 9
Interest coverNo interest cost
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
-1.8%
Mar '25
-1.6%
Jun '25
+1.8%
Sep '25
+5.3%
Dec '25
+6.2%
Mar '26
+4.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.1B, diluted EPS $1.51.
Compare with peers
COO Cooper Companies, Inc.46 WST West Pharmaceutical Se...44Other Health Care Supplies companies by X-Ray Score.
Fundamentals checklist
● 7 Good · ● 7 Average · ● 1 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldAverage
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Good
Revenue growth (3y)Average
Growth consistencyBad
Balance sheet
Current ratioAverage
Interest coverGood
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 63/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $4.0B | $3.7B | $3.9B | $4.0B | $4.0B |
| Operating income | $976M | $643M | $643M | $608M | $546M |
| Net income | $772M | $362M | $445M | $421M | $410M |
| Operating cash flow | $1.2B | $569M | $786M | $738M | $593M |
| Operating margin | 24.7% | 17.2% | 16.7% | 15.2% | 13.5% |
| Free cash flow | $771M | $277M | $608M | $623M | $491M |
| Diluted EPS | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
5 bullish · 3 neutral · 8 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
1 bullish · 1 neutral · 6 bearish
Moving averages (daily)
| SMA 10 | 143.1 | Bullish |
| EMA 10 | 144.8 | Bullish |
| SMA 20 | 144.7 | Bullish |
| EMA 20 | 145.9 | Bullish |
| SMA 50 | 154.3 | Bearish |
| EMA 50 | 152.7 | Bearish |
| SMA 100 | 164.4 | Bearish |
| EMA 100 | 159.5 | Bearish |
| SMA 200 | 169.5 | Bearish |
| EMA 200 | 164.4 | Bearish |
Oscillators (daily)
| RSI (14) | 49.78 | Neutral |
| MACD (12, 26) | -2.40 | Bearish |
| Momentum (12) | 1.35 | Bullish |
| Stochastic %K (14) | 65.12 | Neutral |
| Williams %R (14) | -34.88 | Neutral |
| CCI (20) | 103.0 | Bearish |
Pivot points (classic, last session)
S3 138.7 | S2 142.4 | S1 144.9 | Pivot 148.6 | R1 151.0 | R2 154.7 | R3 157.1 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
ALGN SEC filings
31 Aug 2026
8-KSEC EDGAR
Director or officer change
5 Aug 2026
10-QSEC EDGAR
Quarterly report
29 Jul 2026
8-KSEC EDGAR
Regulation FD disclosure
29 Jul 2026
8-KSEC EDGAR
Results of operations
9 Jul 2026
8-KSEC EDGAR
Director or officer change
22 Jun 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
20 May 2026
8-KSEC EDGAR
Shareholder vote results
6 May 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.